Jasper Ridge Partners’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-19,250
| Closed | -$30.6K | – | 154 |
|
|
2024
Q1 | $30.6K | Hold |
19,250
| – | – | ﹤0.01% | 150 |
|
|
2023
Q4 | $16.5K | Sell |
19,250
-284,242
| -94% | -$244K | ﹤0.01% | 146 |
|
|
2023
Q3 | $325K | Sell |
303,492
-44,758
| -13% | -$47.9K | 0.02% | 111 |
|
|
2023
Q2 | $902K | Hold |
348,250
| – | – | 0.05% | 82 |
|
|
2023
Q1 | $1.42M | Hold |
348,250
| – | – | 0.07% | 71 |
|
|
2022
Q4 | $1.75M | Buy |
348,250
+29,500
| +9% | +$148K | 0.1% | 62 |
|
|
2022
Q3 | $4.17M | Hold |
318,750
| – | – | 0.28% | 41 |
|
|
2022
Q2 | $4.09M | Buy |
318,750
+7,500
| +2% | +$96.1K | 0.25% | 40 |
|
|
2022
Q1 | $4.75M | Buy |
311,250
+1,000
| +0.3% | +$15.3K | 0.23% | 45 |
|
|
2021
Q4 | $5.5M | Hold |
310,250
| – | – | 0.21% | 47 |
|
|
2021
Q3 | $6.52M | Hold |
310,250
| – | – | 0.29% | 48 |
|
|
2021
Q2 | $6.12M | Buy |
310,250
+1,500
| +0.5% | +$29.6K | 0.31% | 46 |
|
|
2021
Q1 | $8.98M | Hold |
308,750
| – | – | 0.41% | 27 |
|
|
2020
Q4 | $9.35M | Hold |
308,750
| – | – | 0.41% | 29 |
|
|
2020
Q3 | $4.91M | Hold |
308,750
| – | – | 0.28% | 39 |
|
|
2020
Q2 | $6.1M | Hold |
308,750
| – | – | 0.42% | 29 |
|
|
2020
Q1 | $3.81M | Buy |
308,750
+1,750
| +0.6% | +$21.6K | 0.3% | 31 |
|
|
2019
Q4 | $5.68M | Sell |
307,000
-43,000
| -12% | -$795K | 0.37% | 24 |
|
|
2019
Q3 | $4.85M | Buy |
350,000
+1,000
| +0.3% | +$13.9K | 0.25% | 25 |
|
|
2019
Q2 | $5.11M | Buy |
+349,000
| New | +$5.11M | 0.21% | 23 |
|